Artemisinin-naphthoquine plus lower-dose primaquine to treat and prevent recurrence of Plasmodium vivax malaria: an open-label randomized and non-inferiority trial

Artemisinin-naphthoquine plus lower-dose primaquine to treat and prevent recurrence of Plasmodium vivax malaria: an open-label randomized and non-inferiority trial

Abstract Background Plasmodium vivax malaria, with the widest geographic distribution, can cause severe disease and death. Primaquine is the main licensed antimalarial drug that can kill hypnozoites. The dose-dependent acute haemolysis in individuals with glucose-6-phospate dehydrogenase (G6PD) defi...

Full description

Bibliographic Details
Main Authors: Hui Liu, Jian-Wei Xu, Dao-Wei Deng, Bi Yaw, Hkawn Shawng Nbwi, Chun Wei, Xing-Wu Zhou, Jian-Xiong Li
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Parasites & Vectors
Subjects:
Plasmodium vivax malaria
Artemisinin-naphthoquine
Primaquine
Radical cure efficacy
Safety
Adherence
Online Access:https://doi.org/10.1186/s13071-023-06058-8

Internet

https://doi.org/10.1186/s13071-023-06058-8

Similar Items